Molecular Cancer Therapeutics (MCT)

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology. The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts: Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly. Sufficient detail is provided to facilitate repetition of the experiments to verify data. Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies. Appropriate replicates in cellular studies are used. Relevant cell lines, animal models, and assays are utilized. Studies must be performed according to AACR and Institutional Guidelines. Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions. Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies. Appropriate controls are employed for all experiments (especially inactive analog compounds). In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated.

Molecular Cancer Therapeutics (MCT) is :-

• International, Peer-Reviewed, Open Access, Refereed, Cancer Therapeutics, Translational Medicine, Pharmacology, Oncology, Molecular Biology, Drug Development , Online or Print , Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1535-7163, E-ISSN: 1538-8514, Established: 2001, Impact Factor: 5.5
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE